CNBC October 31, 2024
Happy Thursday! New research showing additional health benefits of the weight loss drug Wegovy seems to crop up every week.
This time around, Novo Nordisk‘s blockbuster treatment helped reduce knee pain in patients with a type of arthritis and obesity, according to research published Wednesday in the New England Journal of Medicine.
The study was funded by Novo Nordisk, which is conducting several studies on the other potential treatment uses of semaglutide, the active ingredient in Wegovy.
The results of the 68-week trial could be a big deal for the Danish drugmaker: It could pave the way for regulatory approval of semaglutide for osteoarthritis, a degenerative joint disease that causes the cartilage and bone in your joints to break...
Today's Sponsors
Today's Sponsor